Nextgen rbis development, modernization and enhancement (DME)
Ended Awarded Last action
- Contract number
- 75F40123F19004
- Awardee
-
Booz Allen Hamilton Inc. UEI JCBMLGPE6Z71 Part of Booz Allen Hamilton Holding Corporation
- Awarding agency
-
Food and Drug Administration
Department of Health and Human Services
- Obligated
- $10,512,655
Award facts
- Contract value 100% obligated
- $10,512,655.14 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541511 Custom Computer Programming Services
- Competition
- Full and Open Competition Multiple Award, Fair Opportunity
- Pricing
- Labor Hours
- Place of performance
- Calverton, MD 20705, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | -$5,965 | |
| Other Administrative Action | $0 | |
| Original award | $10,518,620 |
About this award
Booz Allen Hamilton Inc., a McLean, Virginia-based management and technology services firm, received a no-cost extension modification to its NextGen RBIS (Regulatory Business Information System) Development, Modernization and Enhancement contract with the Food and Drug Administration. The contract, awarded March 23, 2023, carries a ceiling value of $10.5 million and operates under a Blanket Purchase Agreement (BPA) call against the General Services Administration's Multiple Award Schedule. Work is performed in Calverton, Maryland, with an ultimate completion date of April 14, 2024. The contract utilizes labor-hour pricing and does not carry a small business set-aside designation, reflecting Booz Allen Hamilton's positioning as a large business prime contractor.
The RBIS modernization effort supports the FDA's regulatory science and submission infrastructure capabilities. Booz Allen Hamilton's extensive experience in healthcare technology modernization, enterprise systems development, and regulatory science optimization positions it well for this initiative. The FDA contract aligns with the company's broader portfolio of civilian agency work, which includes significant engagement in healthcare environmental programs, data services, and biomarker tracking support across multiple federal health and science agencies. The no-cost extension maintains project continuity while allowing the contractor and agency to complete development and enhancement activities supporting the FDA's regulatory mission.
Quick answers
Who was awarded contract 75F40123F19004?
75F40123F19004 was awarded to Booz Allen Hamilton Inc. by Food and Drug Administration (Department of Health and Human Services) on March 23, 2023.
How much is contract 75F40123F19004 worth?
The government has obligated $10,512,655 on 75F40123F19004.
Is contract 75F40123F19004 an order under another contract?
Yes. 75F40123F19004 is a BPA call under GS35F386DA-75F40122A00013, a blanket purchase agreement, on Multiple Award Schedule (MAS).
Was contract 75F40123F19004 competed?
The extent of competition for 75F40123F19004 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award